Real‐world effectiveness of vedolizumab compared to anti‐TNF agents in biologic‐naïve patients with ulcerative colitis: A two‐year propensity‐score‐adjusted analysis from the prospective, observational VEDOIBD‐study

维多利祖马布 医学 溃疡性结肠炎 内科学 倾向得分匹配 观察研究 胃肠病学 粪钙保护素 炎症性肠病 钙蛋白酶 疾病
作者
Bernd Bokemeyer,Sandra Plachta‐Danielzik,Romina di Giuseppe,Philipp Efken,W Mohl,Thomas Krause,M Hoffstadt,Robert Ehehalt,Leo Trentmann,Axel Schweitzer,Petra Jessen,Petra Hartmann,Stefan Schreiber
出处
期刊:Alimentary Pharmacology & Therapeutics [Wiley]
卷期号:58 (4): 429-442 被引量:9
标识
DOI:10.1111/apt.17616
摘要

Summary Background This observational real‐world evidence (RWE) study is based on prospectively collected data from the VEDO IBD registry study. Aim To compare the effectiveness of vedolizumab and anti‐TNF agents in biologic‐naïve patients with ulcerative colitis (UC) at the end of induction and during maintenance treatment. Methods Between 2017 and 2020, we enrolled 512 patients with UC starting therapy with vedolizumab or an anti‐TNF agent in 45 IBD centres across Germany. We excluded biologic‐experienced patients and those with missing partial Mayo (pMayo) outcomes; this resulted in a final sample of 314 (182 on vedolizumab and 132 on an anti‐TNF agent). The primary outcome was clinical remission measured using pMayo score; any switch to a different biologic agent was considered an outcome failure (modified ITT analysis). We used propensity score adjustment with inverse probability of treatment weighting to correct for confounding. Results During induction therapy, clinical remission was relatively low and similar in vedolizumab‐ and anti‐TNF‐treated patients (23% vs. 30.4%, p = 0.204). However, clinical remission rates after two years were significantly higher for vedolizumab‐treated patients than those treated with an anti‐TNF agent (43.2% vs. 25.8%, p < 0.011). Among patients treated with vedolzumab, 29% switched to other biologics, versus 54% who had received an anti‐TNF agent. Conclusion After two years of treatment, vedolizumab resulted in higher remission rates than anti‐TNF agents.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
KingXing发布了新的文献求助10
1秒前
TH1223完成签到,获得积分10
1秒前
bei完成签到 ,获得积分10
2秒前
Bio应助混子小高采纳,获得30
2秒前
yao学渣完成签到 ,获得积分10
3秒前
不二臣发布了新的文献求助10
4秒前
可爱的函函应助kkk采纳,获得10
4秒前
斯文败类应助偷乐采纳,获得10
4秒前
Ava应助mariawang采纳,获得10
5秒前
girl发布了新的文献求助10
5秒前
orixero应助szl采纳,获得10
5秒前
自然初露关注了科研通微信公众号
6秒前
yu完成签到 ,获得积分10
6秒前
KingXing完成签到,获得积分10
7秒前
粗犷的灵松完成签到 ,获得积分10
7秒前
yyyyy关注了科研通微信公众号
9秒前
小姚发布了新的文献求助10
9秒前
wjw完成签到,获得积分10
10秒前
10秒前
毛小驴完成签到,获得积分10
11秒前
谢俏艳完成签到,获得积分10
11秒前
lm发布了新的文献求助10
11秒前
11秒前
11秒前
852应助咕噜咕噜咕嘟咕嘟采纳,获得10
12秒前
12秒前
小哥门完成签到,获得积分10
13秒前
Puan发布了新的文献求助10
13秒前
13秒前
sylnd126发布了新的文献求助10
14秒前
15秒前
峥2发布了新的文献求助10
15秒前
15秒前
吵吵robot发布了新的文献求助10
15秒前
16秒前
Nami发布了新的文献求助10
16秒前
吴丹完成签到,获得积分10
18秒前
18秒前
开放雪碧完成签到,获得积分10
18秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988786
求助须知:如何正确求助?哪些是违规求助? 3531116
关于积分的说明 11252493
捐赠科研通 3269766
什么是DOI,文献DOI怎么找? 1804771
邀请新用户注册赠送积分活动 881870
科研通“疑难数据库(出版商)”最低求助积分说明 809021